Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1_157-165 tumor-specific peptide

Journal article

Virus-based tumour vaccines offer many advantages compared to other antigen-delivering systems. They generate concerted innate and adaptive immune response, and robust CD8+ T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis antigen, NY-ESO-1 (NY-ESO-1 S-FLU). Intranasal or intramuscular immunization of NY-ESO-1 S-FLU virus in mice elicited a strong NY-ESO-1-specific CD8+ T cell response in lungs and spleen that resulted in the regression of NY-ESO-1-expressing lung tumour and subcutaneous tumour, respectively. Combined administration with anti-PD-1 antibody, NY-ESO-1 S-FLU virus augmented the tumour protection by reducing the tumour metastasis. We propose that the antigen delivery through S-FLU is highly efficient in inducing antigen-specific CD8+ T cell response and protection against tumour development in combination with PD-1 blockade

Authors: Shenderov, E; Kandasamy, M; Gileadi, U; Chen, J; Shepherd, D

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BMJ Publishing Group
• Journal: Journal for ImmunoTherapy of Cancer
• Volume: 9
• Issue: 6
• Pages: e002544-e002544
• Publication date: 2021-06-04
• Acceptance date: 2021-05-16
• DOI: 10.1136/jitc-2021-002544
• EISSN: 2051-1426
• ISSN: 2051-1426
• Language: English
• Keywords: Genetics; Human leukocyte antigen; Immunology; T-cell receptor; In vitro; Biology; T cell; Antigen; Molecular biology; Immune system; CD8; Cancer research; Immunotherapy; Cytotoxic T cell